ERBB2 and cancer: The molecular design of gemcitabine-(C4-amide)-[anti-HER2/neu] and related covalent gemcitabine immunochemotherapeutics [22,23] result in the synthesis of an anti-cancer preparation that affords a more prolonged plasma pharmacokinetic profiles for the gemcitabine moiety.